Home › NDC Lookup › RxCUI directory › RxCUI 1665514

Flibanserin 100 MG Oral Tablet — RxCUI 1665514

RxNorm drug concept · Semantic clinical drug
RxCUI 1665514 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1665514
Official nameFlibanserin 100 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Flibanserin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • HSDD — hypoactive sexual desire disorder — is a medical condition where your desire for sex has significantly dropped from what it used to be, it bothers you or is affecting your r...
  • What exactly is HSDD, and how do I know if Addyi is right for me?
  • Addyi must be taken at bedtime — that's not just a suggestion, it's a safety requirement. The medication can cause low blood pressure, dizziness, fainting, and drowsiness. Taking i...
  • Why do I have to take Addyi at bedtime? Can I just take it in the morning?
📖 Read our full Flibanserin guide →

🕸️ Concept Web — How Flibanserin 100 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Flibanserin 100 MG Oral Tablet RxCUI 1665514

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Flibanserin 1665509
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Addyi 1666386
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Flibanserin Oral Tablet 1665513
    • Flibanserin Oral Product 1665511
    • Flibanserin Pill 1665512
    • Flibanserin Oral Tablet [Addyi] 1666388
    • Addyi Oral Product 1666389
    • Addyi Pill 1666390
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Flibanserin 100 MG SCDC · 1665510
  • Flibanserin Oral Tablet SCDF · 1665513
  • Flibanserin Oral Product SCDG · 1665511
  • Flibanserin Pill SCDG · 1665512

Brand-Name Concepts

  • Flibanserin 100 MG Oral Tablet [Addyi] SBD · 1666391
  • Flibanserin 100 MG [Addyi] SBDC · 1666387
  • Flibanserin Oral Tablet [Addyi] SBDF · 1666388
  • Addyi Oral Product SBDG · 1666389
  • Addyi Pill SBDG · 1666390
  • Addyi BN · 1666386

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1665514 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
58604-0214-30 1 BOTTLE in 1 CARTON (58604-214-30) / 30 TABLET, FILM COATE... ADDYI Sprout Pharmaceuticals, Inc. 2015-08-18
Observed labelers: Sprout Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.